Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

BCR :: ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B. Leske, Delphine Rea, Stacey Phan, Kaeli B. Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P. Jacobson, Neil P. Shah

Blood (2024) 144 (6): 639–645.

https://doi.org/10.1182/blood.2023022538

Published: 2024

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben A. Mesa, Claire N. Harrison, Giovanni Barosi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Vishwanath Gharpure, Christopher Hernandez, Tianhua Wang, Moshe Talpaz

Blood (2021) 138 (Supplement 1): 389.

https://doi.org/10.1182/blood-2021-147607

Published: 2021

Journal Articles

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Brady L. Stein, MD MHSc, Kamal Patel, MD, Robyn M. Scherber, MD, Jingbo Yu, MD PhD, Dilan Paranagama, PhD, Carole B. Miller, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137144

Published: 2020

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Anem Waheed, MD MPH, Angie Mae Rodday, PhD MS, Anita J Kumar, MD MS, Kenneth B. Miller, MD, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2018-99-111921

Published: 2018

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Blood (2016) 128 (22): 1218.

https://doi.org/10.1182/blood.V128.22.1218.1218

Published: 2016

Journal Articles

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

Carole B. Miller, MD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Ahmad B. Naim, MD, William Sun, PhD, Brian Gadbaw, MD, Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4070.

https://doi.org/10.1182/blood.V126.23.4070.4070

Published: 2015

Journal Articles

Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Ruben A. Mesa, Carole B. Miller, MD, John O. Mascarenhas, MD MS, Maureen Thyne, PA, Sara Goldberger, LCSW-R, Dilan C. Paranagama, PhD, Shreekant V. Parasuraman, PhD, Salman Fazal, MD, Ahmad B. Naim, MD, James Mangan, MD PhD

Blood (2015) 126 (23): 4077.

https://doi.org/10.1182/blood.V126.23.4077.4077

Published: 2015

Journal Articles

Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States

Shreekant V. Parasuraman, PhD, Ahmad B. Naim, MD, Dilan C. Paranagama, PhD, Maureen Thyne, PA, Sara Goldberger, LCSW-R, John O. Mascarenhas, MD MS, James Mangan, MD PhD, Salman Fazal, MD, Carole B. Miller, MD, Ruben A. Mesa

Blood (2015) 126 (23): 5561.

https://doi.org/10.1182/blood.V126.23.5561.5561

Published: 2015

Journal Articles

Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center

Sandy W. Wong, MD, Melissa Warner, BS, Alejandro Moreno-Koehler, MPH, Athena Kritharis, MD, Michael E Coyle, MD, Deborah Black, RN, BSN, Valerie Relias, PharmD, BCOP, Terry Fogaren, RN, BSN, Nancy Cody Lyons, NP, Francois Toka, NP-C, Denise Larivee, RN, Hedy Smith, MD PhD, Andrew M. Evens, DO, MSc, Grace Kao, MD, Kellie Sprague, MD, Andreas K. Klein, MD, Kenneth B. Miller, MD, Raymond L. Comenzo, MD

Blood (2015) 126 (23): 5496.

https://doi.org/10.1182/blood.V126.23.5496.5496

Published: 2015

Journal Articles

Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease

Sandy W. Wong, MD, Raymond L. Comenzo, MD, Todd F. Roberts, MD MSC, FRCP (C), Kellie Sprague, MD, Kenneth B. Miller, MD

Blood (2015) 126 (23): 5461.

https://doi.org/10.1182/blood.V126.23.5461.5461

Published: 2015

Journal Articles

Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Salman Fazal, MD, Carole B. Miller, MD, John O. Mascarenhas, MD MS, Maureen Thyne, PA, Sara Goldberger, LCSW-R, Dilan C. Paranagama, PhD, Shreekant V. Parasuraman, PhD, Ahmad B. Naim, MD, James Mangan, MD PhD, Ruben A. Mesa

Blood (2015) 126 (23): 5184.

https://doi.org/10.1182/blood.V126.23.5184.5184

Published: 2015

Journal Articles

Practical Measures of Clinical Benefit with Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Carole B Miller, MD, Rami S Komrokji, MD, Ruben Mesa, MD, William Sun, PhD, Michael Montgomery, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3202.

https://doi.org/10.1182/blood.V124.21.3202.3202

Published: 2014

Journal Articles

Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis

Ojas H. Vyas, MD, Esha Kaul, MD, Aaron S. Rosenberg, MD, Gunjan L Shah, MDMS, Urvi Ajay Shah, MD, Raymond L. Comenzo, MD, Grace Shih-Hui Kao, MD, Andrew M. Evens, DO, MSc, Hedy Smith, MDPhD, Andreas K. Klein, MD, Kenneth B. Miller, MD, Kellie A. Sprague, MD

Blood (2014) 124 (21): 3170.

https://doi.org/10.1182/blood.V124.21.3170.3170

Published: 2014

Journal Articles

Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY

Ruben Mesa, MD, Carole B Miller, MD, Maureen Thyne, PA, James Mangan, MD PhD, Sara Goldberger, LCSW-R, Salman Fazal, MD, Xiaomei Ma, PhD, Wendy Wilson, RN, MSN, OCN, David G Dubinski, MBA, John Boyle, PhD, John O Mascarenhas, MD MS

Blood (2014) 124 (21): 4827.

https://doi.org/10.1182/blood.V124.21.4827.4827

Published: 2014

Journal Articles

Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States

Blood (2014) 124 (21): 3183.

https://doi.org/10.1182/blood.V124.21.3183.3183

Published: 2014

NARROW

BCR :: ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States

Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center

Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease

Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Practical Measures of Clinical Benefit with Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis

Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY

Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only